Table 2.

Patient characteristics and response

Pt #GenderAge (y)HistologyMetastatic disease sitePrognostic criteria MSKCI/UISS# VaxBest clinical responseDuration of response in monthsAdditional treatmentSurvival in months
01M70ccLung, adrenalInt/Int4SD17.5Soafenib, sunitinib, bevacizumab47.0+
02M42ccLungInt/Int5PR9.2Bevacizumab, sunitinib46.3+
03M76ccLN (mediastinal, RP, pelvic)L/Int2SD6.1Bevacizumab12.6
04M64ccLung, LN (mediastinal, para-aortic)Int/Int3CR43.3+None43.3+
05M71sLungL/Int1PD1.4Bevacizumab + IFN42.4+
06F61ccBoneL/Int2PD1.6Bevacizumab, sorafenib14.1
07F50ccLung, adrenal, LNInt/Int3PR9.0Sunitinib, sorafenib, bevacizumab38.5+
08M57ccLung, bones, LNInt/Int3CR12.4Sorafenib37.3+
09M69ccLung, liver, LNInt/High5PR4.0Sorafenib, temsirolimus36.4+
10M64ccBone, LNInt/Int5SD7.0Sorafenib33.4+
11M54ccLung, LNL/L4PR2.8Sorafenib, sunitinib, bevacizumab28.0
12M61ccLung, LNL/Int3PR9.0Not known32.3+
13M64ccLungL/High4SD3.2Sorafenib7.4
14M44ccLungInt/Int5SD25.8+None25.8+
15F70mLung, liverL/Int5SD4.0Sorafenib, sunitinib24.0+
16F66ccLung, LNInt/Int4PR7.0Sunitinib20.4+
17M47SSkin, LN, LungInt/Int3CR19.3+None19.3+
18F64ccBone, LN, Lung, AdrenalInt/Int1PD1.3Sorafenib6.4

Abbreviations: Pt, patient; MSKCI, Memorial Sloan Kettering Cancer Institute Low, Intermediate, High risk factors; UISS, UCLA Integrated Staging System low, Intermediate, High risk factors; Vax, vaccination; M, male; cc, clear cell; s, sarcomatoid; F, female; SD, stable disease; PR, partial response; PD, progression of disease; +, continuing; LN, lymphnode; m, mixed including clear cell, chromophobe, and papillary.